|
Tuberculosis is primarily a disease of the respiratory system, and is spread by coughing and sneezing. Each year approximately 2 million people die from this curable disease. The breakdown in health services, the spread of HIV/AIDS and the emergence of multidrug-resistant TB are contributing to the worsening impact of this disease. The WHO has estimated that between 2002 and 2020, approximately 1000 million people will be newly infected, over 150 million people will get sick, and 36 million will die of TB - if control is not further strengthened. In Eastern Europe and Africa, TB deaths are increasing after 40 years of decline. The largest concentration is in Southeast Asia. |
Bangalore Research Institute
This research facility, located in India, combines TB research and manufacturing capabilities.
Global Alliance for TB Drug Development
(TB Alliance)
This partnership seeks to provide a more effective treatment of multidrug-resistant TB and latent TB infection.
Lilly MDR-TB Partnership
This initiative aims to increase the number of trained personnel and drugs available to treat the expanding crisis of multidrug-resistant TB (MDR-TB).
Novartis TB DOTS Donation
Novartis has committed to donate the WHO recommended best TB treatment for half a million patients over five years.
|
|
Novartis Institute for Tropical Diseases (NITD)
The new research center will focus exclusively on the discovery of innovative drugs for the treatment of diseases that are endemic to developing countries.
Stop
TB Partnership
Through its partners, Eli Lilly distributes two critical anti-TB drugs for treatment of MDR-TB to countries including Peru, Russia and the Philippines.
TB Free
This South African partnership trains volunteers to support TB patients' compliance during their six-month treatment.
Helping the Red Cross in the Fight against TB
AstraZeneca and the British Red Cross joining forces in the fight against tuberculosis. |
